Compare H2O America (HTO) vs Novavax Inc (NVAX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
H2O America vs Novavax Inc — how do they compare? H2O America trades at $58.54 (market cap $2.43B), while Novavax Inc trades at $12.75 (market cap $1.82B). The key difference: H2O America is the larger of the two by market cap, and H2O America pays a 3.03% dividend while Novavax Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold H2O America for 40 Days and Novavax Inc for 59 Days on average.
| HTO | NVAX | |
|---|---|---|
Market Cap | $2.43B | $1.82B |
Volume | 593,883 | 6,198,505 |
Sector | Utilities | Health |
52-Week High | $65.43 | $12.56 |
52-Week Low | $44.44 | $6.22 |
Typical Hold Time | 40 Days | 59 Days |
Enterprise Value | $4.22B | $1.39B |
Dividend Yield | 3.03% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
HTO trades at $58.70, up 1.24% with mixed technical signals showing bearish moving averages but bullish oscillators. The company maintains strong profitability with 12.91% net margins and recently completed the Quadvest acquisition through its Texas subsidiary. Analyst consensus remains strongly bullish with 83% buy ratings and a $66.50 price target, representing 13% upside potential from current levels.
The outlook appears favorable given the strategic acquisitions and Dividend King status, though execution risks from recent equity dilution and negative cash flow from investing activities warrant monitoring. The stock offers value with reasonable P/E of 20.45 and consistent earnings beats, supported by institutional accumulation including BlackRock's significant position.
Novavax (NVAX) trades at $12.75, up 13.64% with strong technical momentum and bullish moving averages. The company shows mixed fundamentals with revenue of $1.12B in 2025 and positive net income of $440.30M, though 2026 projections indicate a return to losses. Recent news highlights regulatory approvals for its COVID-19 vaccine and strategic pivot toward Matrix-M adjuvant licensing partnerships.
The outlook remains speculative with high volatility. Opportunities include partnership-driven growth and vaccine demand, but risks involve consistent profitability challenges, high debt-to-asset ratios, and competitive pressures. Analyst sentiment is predominantly bullish (73.9% buy ratings), yet investors should weigh the company's transition phase against financial stability concerns.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About H2O America
H2O America is a utility company that provides essential water and wastewater services, primarily in the United States. The company operates a network of regulated water and wastewater systems, focusing on responsible resource management and high-quality service delivery. HTO aims to expand its operational footprint through acquisitions and internal growth, serving residential, commercial, and industrial customers.
Read more on HTO →About Novavax Inc
Novavax, Inc. is a clinical stage biotechnology company. The Company creates novel vaccines to address a broad range of infectious diseases worldwide using proprietary virus-like particle (VLP) technology.
Read more on NVAX →
